Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TenX Biopharma (TenX) has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize, zanolimumab (HuMax-CD4), from Genmab.
Subscribe to our email newsletter
As per the agreement, Genmab is expected to receive an up-front license fee of $4.5m and will be entitled to milestones and royalties on sales of zanolimumab. TenX will be responsible for all future costs of developing, manufacturing and commercialising zanolimumab.
Gardiner Smith, CEO of TenX, said: “Zanolimumab has promise for treatment of patients with T cell cancers, and potential in other cancer types for which existing therapies are inadequate. We are building a pipeline of new medicines for high unmet need, with a focus on the patient through business efficiency.”
Lisa Drakeman, CEO of Genmab, said: “Genmab is pleased to find a partner who wishes to take zanolimumab forward in development. This is good news for patients who may one day benefit from treatment with zanolimumab.”